Committee Structure
Congress Chair
- Mario L. Rocci Jr., Ph.D., Congress Chair (USA)
Scientific Program Chair
- Ho-Leung Fung, Ph.D., Scientific Program Chair (USA)
Scientific Program Committee Chairs
- Mitsuru Hashida, Ph.D., Asia Scientific Program Committee Chair (Japan)
- Geoffrey T. Tucker, Ph.D., Europe Scientific Program Committee Chair (UK)
- Robert G. Bell, Ph.D., Americas Scientific Program Committee Chair (USA)
FIP Secretary
- Vinod P. Shah, Ph.D. (USA)
Asia Scientific Program Committee
- Tatsuro Irimura, Ph.D. (Japan)
- Ross McKinnon, Ph.D. (Australia)
- In Koo Chun, Ph.D. (Korea)
- Sang Guowei, Ph.D. (China)
Europe Scientific Program Committee
- Theo Dingermann, Ph.D. (Germany)
- Panos Macheras, Ph,D. (Greece)
- Elias Fattal, Ph.D. (France)
- Arto Urtti, Ph.D. (Finland)
Americas Scientific Program Committee
- Teresa Dalla Costa, Ph.D. (Brazil)
- Gordon McKay, Ph.D. (Canada)
- Tony DeStefano, Ph.D. (USA)
Scientific Program Committee Advisors
- Wang Xiaoliang, Ph.D. (China)
- Liu Chunguang (China)
- Hans Linden (Sweden)
Mario L. Rocci, Ph.D.
Dr. Mario Rocci has over 29 years of experience in the industry and currently serves as the Executive Vice President of Global Bioanalytical Sciences at ICON Development Solutions, overseeing ICON’s globally expanding Bioanalytical Sciences group, incorporating LC/MS/MS, Immunoassay and biomarker service offerings. Dr. Rocci’s vast experience includes positions such as Head of the Laboratory of Investigative Medicine and Research Associate Professor of Medicine at Thomas Jefferson University, where he was part of a team of Clinical Pharmacologists conducting Phase I-IV clinical studies on drugs undergoing development. Dr. Rocci was also a Clinical Associate Professor of Pharmacy Practice at the Philadelphia College of Pharmacy and Science.
Dr. Rocci is well known throughout the pharmaceutical industry and has recently served as the 2004 President of the American Association of Pharmaceutical Scientists (AAPS), having previously been elected to a three year term on the AAPS Board of Directors. He also serves on the Board of Directors for the International Pharmaceutical Federation (FIP) and is Chairman of the Board of the Product Quality Research Institute (PQRI).
Dr. Rocci has authored over 125 scientific publications and has extensive experience in the pharmaceutical sciences and the regulatory requirements of the FDA. He has over 25 years of experience in the pharmaceutical industry.
Dr. Rocci earned a Ph.D. in Pharmaceutics and a B.S. in Pharmacy from the State University of New York at Buffalo.
Ho-Leung Fung, Ph.D.
Dr. Ho-Leung Fung is a Professor of Pharmaceutical Sciences at UB. He received his undergraduate pharmacy training at the Victorian College of Pharmacy (now a faculty of Monash University, Australia), and his Ph.D. degree in Analytical Pharmaceutical Chemistry and Pharmaceutics in 1970 from the University of Kansas. Awards include Research Achievement Awards from the American Association of Pharmaceutical Scientists (AAPS, in 1988), and the American Pharmaceutical Association in 1992, a MERIT grant award from the National Heart, Lung and Blood Institute in 1988, the Takeru and Aya Higuchi Award from the Academy of Pharmaceutical Sciences and Technology Japan in 1995. He has been a member of the NIH Pharmacology Study Section (1988-1992), member (1995-7) and Chairman (1996-8) of the NIGMS Pharmacological Sciences Review Committee. He served as President of AAPS in 1997, and received the honorary Doctor of Laws (LL.D.) degree from Monash University of Australia in 2008. He is the Scientific Program Chair of the Pharmaceutical Sciences World Congress 2010. His research interests involve the bioanalysis, drug delivery, pharmacokinetics and pharmacodynamics of nitric oxide donors, and mechanisms of nitric oxide modulation.
Mitsura Hashida, Ph.D.
Mitsuru Hashida, Ph.D. is a Professor in the Graduate School of Pharmaceutical Sciences and Institute for Integrated Cell-Material Sciences at Kyoto University. He is currently Chairman of the Board of Pharmaceutical Sciences (BPS) of the International Pharmaceutical Federation (FIP) after eight years service as FIP vice-president. He received his Ph.D. degree from Kyoto University in 1979 and returned to its faculty in 1980 following postdoctoral fellowship at the University of Kansas. His research interests include development and evaluation of novel drug delivery systems for proteins and genes, and analysis of oral and transdermal drug absorption; he is the author or co-author of about 390 scientific articles. He was the recipient of the Takeru and Aya Higuchi Memorial Prize in 1990, FIP Pharmaceutical Scientist of the Year 1998 Award, Academy of Pharmaceutical Sciences and Technology, Japan (APSTJ) Award in 1999, Pharmaceutical Society of Japan (PSJ) Award in 2005, Controlled Release Society (CRS) Founders' Award in 2005, and American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Pharmaceutics and Drug Delivery in 2007. Dr. Hashida is a member of Science Council of Japan, and a President of Japan Society of Drug Delivery System (JSDDS) , vice-president of PSJ, and immediate past president of APSTJ.
Geoffrey T. Tucker, Ph.D.
Dr. Geoff Tucker is Professor of Clinical Pharmacology and Head of the Academic Unit of Clinical Pharmacology at the University of Sheffield, UK. He graduated in pharmacy (1964) with a Ph.D (1967) from the University of London. He has over 350 publications in the areas of pharmacokinetics, drug metabolism, pharmacogenetics and the pharmacology of drugs used in anaesthesia (‘Highly Cited Author – Pharmacology: Institute of Scientific Information (ISI)). He was Chairman of the Editorial Board of the British Journal of Clinical Pharmacology from 1995-2002; he is a Board Member of several others, a past Member of the Council of the British Pharmacological Society, an Expert Advisor to the Committee on Safety of Medicines (UK), past Council Member of the Clinical Division of IUPHAR, past Member – Board of Pharmaceutical Sciences of the Federation Internationale Pharmaceutique (FIP), Councillor – International Society for the Study of Xenobiotics (ISSX), Member of the International Advisory Board of the African Institute of Biomedical Science & Technology, Visiting Professor at the Universities of Harvard, Cincinnati and Otago and the US FDA, an elected Fellow of the Royal College of Anaesthetists, of the Royal College of Physicians of Edinburgh, of the Faculty of Pharmaceutical Medicine, Royal College of Physicians UK and of the British Pharmacological and Toxicological Societys, and Chairman of Simcyp Ltd, a University of Sheffield spin-out company. He received the Lilly Prize of the British Pharmacological Society in 2000 for contributions to clinical pharmacology over many years, and in 2004 the New, Safer, Faster Drug Development Award from the European Federation of Pharmaceutical Sciences.
Robert G. Bell, Ph.D.
Dr. Robert G. Bell is President/Owner of Drug and Biotechnology Development LLC, and a consultant to the international pharmaceutical industry and academia for biological, drug and device development. Dr. Bell received his B.S. in Chemistry, M.S. in Food Science and Human Nutrition and Ph.D. in Pharmaceutics from the University of Florida. Dr. Bell is an Adjunct Professor of Pharmaceutics, a member of the National Advisory Board and recipient of the Distinguished Alumnus Award at the College of Pharmacy, University of Florida and Affiliate Faculty at the College of Pharmacy at Virginia Commonwealth University. Dr. Bell has published over 100 abstracts, 17 papers, several book chapters and patents. Dr. Bell’s research interests include many aspects of drug, device and biologic research and development including pharmaceutical and biomedical analysis, quality, clinical development, CMC, health related quality of life outcomes, vaccines, follow on protein products (biogenerics), combination drug-devices, and the clinical and pharmaceutical development of women’s heath and oncology therapeutics. Dr. Bell has served in various leadership capacities within the American Association of Pharmaceutical Scientists (AAPS) and is a member of the American Society of Clinical Oncology, American Urology Association, International Society of Andrology, American Chemical Society, American College of Pharmacology and AAPS.